Curis (CRIS) Corporate presentation summary

Emavusertib clinical and preclinical highlights

• Demonstrated dual inhibition of IRAK4 and FLT3, targeting key pathways in CLL, NHL, and AML, with proof-of-concept data showing improved response rates over standard of care in multiple indications.

• In PCNSL, achieved 63% ORR in BTKi-naïve and 27% ORR in BTKi-experienced patients; in mFLT3 AML, achieved 38% CR/CRh compared to 21% for standard of care.

• Preclinical and clinical data support deeper and more durable responses when emavusertib is combined with BTK inhibitors, especially in NHL and CLL.

• Ongoing registrational studies in PCNSL and expansion into larger NHL subtypes, including CLL, with early data showing consistent activity across subtypes.

• In AML, emavusertib monotherapy shows potential to outperform gilteritinib, with plans for a head-to-head registrational study.

Safety and tolerability

• Emavusertib has been well tolerated in both NHL and AML, with no dose-limiting myelosuppression or CNS toxicities observed.

• In NHL, 81 patients treated with durations over 1-2 years; most common grade 3+ adverse events included neutropenia and increased CPK.

• In AML, 102 patients treated; 33% experienced grade 3+ treatment-related adverse events, with neutropenia and increased CPK most common.

• No new safety signals identified, and emavusertib crosses the blood-brain barrier.

Market opportunity and study design

• Addressing large markets: $12B for NHL, $9B for CLL, $3B for WM and other NHL, $2.4B for AML.

• Registrational studies in PCNSL designed for both accelerated and full approval, with benchmarks set against current standards.

• CLL Phase 2 study aims to enable fixed-duration, time-limited oral therapy, potentially changing the treatment paradigm.

• Head-to-head pivotal study planned versus gilteritinib in relapsed/refractory mFLT3 AML.